List of works - Constantine S Mitsiades

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

scientific article

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma ⬇️

scientific article published on August 18, 2011

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

scientific article

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

scientific article

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

scientific article published in August 2002

Antimyeloma activity of heat shock protein-90 inhibition.

scientific article published on 18 October 2005

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

scientific article

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

scientific article published on December 2003

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

scientific article

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

scientific article published in June 2002

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

scientific article (publication date: 16 September 2011)

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma

scientific article published on November 2006

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

scientific article

Bortezomib in the front-line treatment of multiple myeloma

scientific article published on July 2008

Bortezomib in the management of multiple myeloma ⬇️

scientific article published on September 8, 2009

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

scientific article published on 12 May 2009

Bortezomib: proteasome inhibition as an effective anticancer therapy

scientific article

Can thalidomide improve outcome in patients with multiple myeloma?

scientific article published on 01 November 2006

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

scientific article

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

scientific article published on 19 August 2004

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function

scientific article

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia

scientific article published in February 2010

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

scientific article published on July 2002

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

scientific article published on June 2015

Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

scientific article published on 29 May 2007

Emerging drugs in multiple myeloma

scientific article published on March 2007

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

scientific article published on April 2009

Emerging trends in the clinical use of bortezomib in multiple myeloma

scientific article

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study ⬇️

scientific article published on December 13, 2012

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

scientific article published in August 2005

From the bench to the bedside: emerging new treatments in multiple myeloma

scientific article published on December 2007

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

scientific article

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

scientific article published on 11 April 2011

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

scientific article

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents

scientific article published on 26 April 2012

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

scientific article

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

scientific article

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

scientific article published on 25 September 2003

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

scientific article published on 14 September 2009

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

scientific article published on September 2007

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers ⬇️

scientific article published on January 10, 2011

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

scientific article published on September 2003

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

scientific article published on 24 November 2009

Lenalidomide in multiple myeloma

scientific article published on August 2006

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy ⬇️

scientific article published on June 15, 2010

Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma

scientific article published on 10 June 2008

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

scientific article

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

scientific article

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias

scientific article published on June 1, 2011

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

scientific article published on 01 October 2006

Management of Relapsed and Relapsed/Refractory Multiple Myeloma ⬇️

scientific article published on 01 October 2011

Management of myeloma-associated renal dysfunction in the era of novel therapies

scientific article published on February 2012

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings ⬇️

scientific article published on 07 July 2011

Maximizing the clinical benefit of novel therapies in multiple myeloma

scientific article published on April 2009

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

scientific article published on April 2004

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

scientific article

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells

scientific article published on 13 September 2012

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation

scientific article

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

scientific article published on 12 January 2012

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

scientific article

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

scientific article published on April 2005

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

scientific article published on 26 September 2002

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

scientific article published on 16 January 2003

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

scientific article

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

scientific article

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

scientific article published on July 2007

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

scientific article

NF-kappa B as a therapeutic target in multiple myeloma

scientific article

New drugs for myeloma

scientific article published on June 2007

New proteasome inhibitors in myeloma

scientific article published on December 2012

Novel biological therapies for the treatment of multiple myeloma

scientific article

Novel biologically based therapies for Waldenstrom's macroglobulinemia

scientific article

Novel therapeutic avenues in myeloma: changing the treatment paradigm.

scientific article published on June 2007

Novel therapies in myeloma

scientific article published on November 2007

Novel therapies in the treatment of multiple myeloma

scientific article published on October 2009

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

scientific article published on 01 January 2003

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

scientific article published on 17 January 2006

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

scientific article

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

scientific article

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

scientific article

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias

scientific article

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy ⬇️

scientific article published on October 27, 2011

Proteasome inhibition as a new therapeutic principle in hematological malignancies

scientific article published on October 2006

Proteasome inhibition as a therapeutic strategy for hematologic malignancies

scientific article

Proteasome inhibition in hematologic malignancies

scientific article published in January 2004

Proteasome inhibition in the treatment of cancer

scientific article

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

scientific article published in November 2003

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

scientific article

Proteasome inhibitor therapy in multiple myeloma

scientific article

Proteasome inhibitors as therapeutics

scientific article

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

scientific article

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

scientific article published on 15 June 2009

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

scientific article published in March 2010

Tanespimycin as antitumor therapy.

scientific article

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

scientific article

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

scientific article published on 10 October 2006

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

scientific article published in July 2004

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma ⬇️

scientific article published on February 1, 2011

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* ⬇️

scientific article published on November 22, 2011

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

scientific article published on 11 December 2003

The emerging role of novel therapies for the treatment of relapsed myeloma

scientific article published on February 2007

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

scientific article published on 16 April 2013

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib ⬇️

scientific article published on 07 March 2012

The power of proteasome inhibition in multiple myeloma

scientific article published on 14 November 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

scientific article published on 7 November 2002

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

scientific article published on December 2007

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

scientific article published on 9 June 2006

The treatment of multiple myeloma patients not eligible for asct ⬇️

scientific article published on May 3, 2010

The treatment of relapsed and refractory multiple myeloma

scientific article published on January 2007

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

scientific article published on 14 March 2010

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

scientific article published on August 2007

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

scientific article

List of works by Constantine S Mitsiades

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma ⬇️

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

Antimyeloma activity of heat shock protein-90 inhibition.

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

Bortezomib in the front-line treatment of multiple myeloma

Bortezomib in the management of multiple myeloma ⬇️

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

Bortezomib: proteasome inhibition as an effective anticancer therapy

Can thalidomide improve outcome in patients with multiple myeloma?

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

Emerging drugs in multiple myeloma

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

Emerging trends in the clinical use of bortezomib in multiple myeloma

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study ⬇️

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

From the bench to the bedside: emerging new treatments in multiple myeloma

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers ⬇️

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

Lenalidomide in multiple myeloma

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy ⬇️

Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

Management of Relapsed and Relapsed/Refractory Multiple Myeloma ⬇️

Management of myeloma-associated renal dysfunction in the era of novel therapies

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings ⬇️

Maximizing the clinical benefit of novel therapies in multiple myeloma

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

NF-kappa B as a therapeutic target in multiple myeloma

New drugs for myeloma

New proteasome inhibitors in myeloma

Novel biological therapies for the treatment of multiple myeloma

Novel biologically based therapies for Waldenstrom's macroglobulinemia

Novel therapeutic avenues in myeloma: changing the treatment paradigm.

Novel therapies in myeloma

Novel therapies in the treatment of multiple myeloma

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.